Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
MONTPELLIER, France & CAMBRIDGE, Mass., September 23, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announced the availability of its half-year report.
MONTPELLIER, France & CAMBRIDGE, Mass., September 18, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces registration and connection details for its SENS-601 Program Day, to be held on September 22, 2026.
Sensorion (ENXTPA:ALSEN) has completed a reverse share split, exchanging every 50 existing shares for 1 new share. The consolidated stock is now trading in Paris under a new ISIN. Recent trading shows Sensorion under pressure, with the share price at €9.70 after declines of about 7% over one day, 19% over the past week and 34% across the last month. This continues a longer pattern of weak total shareholder returns over one, three and five years. This softer momentum sits alongside the new...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.